Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination

Patent metadata

Field	Value
Publication number	US-9851358-B2
Application number	US-201515109942-A
Country	US
Kind code	B2
Filing date	Jan 7, 2015
Priority date	Jan 8, 2014
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.

First claim

The invention claimed is:

1. A method for inhibiting or reducing metastatic dissemination in a subject suffering from a cancer comprising the steps of:
i) measuring an expression level of at least one biomarker selected from the group consisting of: soluble CD95L and epithelial-to-mesenchymal transition (EMT) promoting factors in a sample obtained from the subject,
ii) comparing the expression level measured at step i) with a reference expression level of the biomarker determined in an individual who has the same cancer but for whom metastatic dissemination did not occur, and
iii) administering to the subject a therapeutically effective amount of at least one compound selected from the group consisting of C16-ceramide, C16-sphingomyelin and C16-glycosphingolipid when the expression level determined at step i) is higher than the reference biomarker expression level.

2. The method of claim 1 wherein the subject suffers from a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancers, carcinomas, sarcomas, and soft tissue cancers.

3. The method of claim 1 wherein the subject suffers from a triple negative breast cancer.

4. The method of claim 1 wherein the EMT-promoting factor is TGFbeta.

5. The method of claim 1 wherein the C16-ceramide, C16-sphingomyelin or C16-glycosphingolipid is incorporated into liposomal vesicles.

Assignees

• Inserm (Institut National De La Sante Et De La Rech Medicale
• Univ Toulouse 3 Paul Sabatier
• Ct Hospitalier Universitaire Toulouse
• Univ Bourgogne
• Univ Rennes
• Univ Des Antilles Et De La Guyane
• Ecole Des Hautes Etudes En Sante Publique (Ehesp)
• Inserm (Institut National De La Sante Et De La Rech Medicale)
• Univ Rennes
• Univ Des Antilles Et De La Guiyane

Inventors

• Legembre Patrick
• Segui Bruno
• Levade Thierry
• Micheau Olivier

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61K9/127

  Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

• A61K31/164

  of a carboxylic acid with an aminoalcohol, e.g. ceramides · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title